Financial Performance - The company's revenue for Q3 2021 was approximately CNY 3.08 billion, a decrease of 2.34% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 205.32 million, down 32.52% year-on-year[5]. - The net profit excluding non-recurring gains and losses was CNY 166.96 million, a decrease of 40.28% compared to the previous year[5]. - Basic earnings per share for the period was CNY 0.20, reflecting a decline of 32.50% year-on-year[5]. - The diluted earnings per share was CNY 0.174, down 32.35% from the same period last year[5]. - Total operating revenue for the first three quarters of 2021 reached RMB 10,710,170,799.63, an increase of 14.4% compared to RMB 9,363,726,744.19 in the same period of 2020[25]. - Net profit for the first three quarters of 2021 was RMB 799,702,644.46, slightly up from RMB 792,052,011.94 in 2020, reflecting a growth of 1%[28]. - Total profit for the first three quarters of 2021 was RMB 896,554,704.45, down from RMB 944,860,524.54 in 2020, indicating a decrease of 5.1%[28]. Assets and Liabilities - Total assets at the end of the period were approximately CNY 19.54 billion, an increase of 7.05% from the end of the previous year[7]. - Current assets totaled CNY 11.26 billion, up from CNY 10.16 billion, indicating a growth of about 10.87% year-over-year[18]. - Total liabilities amounted to CNY 9.10 billion, up from CNY 8.43 billion, which is an increase of approximately 7.91%[21]. - Total assets as of December 31, 2020, were ¥18,250,454,785.72, increasing to ¥18,349,337,318.43 by January 1, 2021, reflecting a growth of ¥98,882,532.71[39]. - Total liabilities increased from 8,431,088,899.10 to 8,529,971,431.81, a rise of 1.4%[46]. - Current liabilities totaled 6,194,362,158.11, slightly increasing to 6,230,103,370.47, reflecting a 0.6% increase[46]. - Non-current liabilities rose from 2,236,726,740.99 to 2,299,868,061.34, marking an increase of 2.8%[46]. Cash Flow - The company reported a net cash flow from operating activities of CNY 1.37 billion for the year-to-date, an increase of 12.43% compared to the previous year[5]. - Cash flow from operating activities amounted to RMB 9,885,981,372.64, an increase from RMB 8,009,851,969.33 in the previous year[33]. - Operating cash inflow for the first three quarters of 2021 reached ¥10,528,665,529.24, an increase of 15.1% compared to ¥9,145,572,156.50 in the same period of 2020[36]. - The net cash flow from operating activities was ¥1,372,864,799.01, up from ¥1,221,116,088.41 in the first three quarters of 2020, representing a growth of 12.4%[36]. - Net cash outflow from investing activities was ¥403,071,051.46, slightly improved from ¥409,779,193.90 in the first three quarters of 2020[37]. Shareholder Equity - Shareholders' equity attributable to the parent company was CNY 8.66 billion, up 6.46% year-on-year[7]. - The company's equity attributable to shareholders reached CNY 8.66 billion, compared to CNY 8.13 billion, reflecting a growth of about 6.56%[23]. - The company’s total equity attributable to shareholders was 8,131,208,694.81, remaining unchanged[46]. Expenses and Costs - Total operating costs increased to RMB 9,829,243,735.14, up 16.2% from RMB 8,458,535,558.27 in the previous year[25]. - Research and development expenses rose to RMB 386,254,592.42, a 24.9% increase from RMB 309,099,415.11 in the same period last year[25]. - The company reported an investment loss of RMB 15,897,420.02, compared to a loss of RMB 10,345,837.90 in the same period of 2020[28]. - Other comprehensive income after tax was RMB 670,394.85, down from RMB 884,148.78 in the previous year[30]. - The company experienced a credit impairment loss of RMB 29,837,513.78, an improvement from RMB 47,832,613.54 in the same period last year[28]. Government Support - The company received government subsidies amounting to CNY 49.41 million during the quarter, which was higher than the previous year[9].
国药现代(600420) - 2021 Q3 - 季度财报